We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat
Read MoreHide Full Article
Shares of Inari Medical, Inc. (NARI - Free Report) fell 16.9% on May 5, following the company's first-quarter 2022 results.
The company reported first-quarter 2022 net loss per share of 6 cents, narrower than the Zacks Consensus Estimate of 8 cents. The company had reported earnings of 13 cents per share in the year-ago quarter.
Revenue Details
The company reported revenues of $86.8 million, which surged 51.1% from the prior-year quarter. The top line outpaced the Zacks Consensus Estimate by 4.3%. New product introductions and continued U.S. commercial expansion contributed to the improvement.
Q1 Highlights
The company treated 8,800 patients, up 14% on a sequential basis.
Inari Medical, Inc. Price, Consensus and EPS Surprise
Inari Medical unveiled Intri24 — an introducer sheath created to optimize the FlowTriever procedure. Intri24 has become the latest device to be added to the company’s FlowTriever system of purpose-built tools, all for a single price.
Margins
Gross profit in the reported quarter was $76.8 million, up 45.5% year over year. As a percentage of revenues, gross margin in the quarter was 88.5%, down 340 basis points (bps).
Research and development expenses were $16.1 million, up 97.7% from the year-ago quarter. Meanwhile, selling, general and administrative expenses amounted to $63.7 million, up 72.7% on a year-over-year basis.
Operating loss totaled $3.1 million against the year-ago quarter’s operating income of $7.7 million.
Financial Position
The company exited the first quarter with cash, cash equivalents and short-term investments of $338.7 million, up from $176.1 million on a sequential basis.
Net cash provided by operating activities at the end of the first quarter was $9.1 million, compared with $8.8 million in the prior-year quarter.
2022 Revenue Outlook Revised
For 2022, the company projects revenues in the range of $360 million to $370 million (up from the previously guided range of $350-$360 million). The Zacks Consensus Estimate for the same is pegged at $358.2 million.
Our Take
Inari Medical exited the first quarter on a strong note, wherein both earnings and revenues beat the consensus mark. Apart from treating a large number of patients in the quarter under review, the company made substantial progress on all of its growth drivers.
However, the incurrence of operating loss remains a concern. Contraction in gross margin is a woe.
Zacks Rank
Currently, Inari Medical carries a Zacks Rank #3 (Hold).
Key Picks
Some better-ranked stocks in the broader medical space that have announced quarterly results are Omnicell, Inc. (OMCL - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Alkermes plc (ALKS - Free Report) .
Omnicell, carrying a Zacks Rank #2 (Buy), reported first-quarter 2022 adjusted EPS of 83 cents, which beat the Zacks Consensus Estimate by 16.9%. Revenues of $318.8 million outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Omnicell has an estimated long-term growth rate of 16%. OMCL's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 13.4%.
UnitedHealth, carrying a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 1.9%.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.7%.
Alkermes reported first-quarter 2022 adjusted EPS of 12 cents, which beat the Zacks Consensus Estimate of a penny. First-quarter revenues of $278.6 million outpaced the Zacks Consensus Estimate by 6.2%. It currently carries a Zacks Rank #2.
Alkermes has an estimated long-term growth rate of 25.1%. ALKS' earnings surpassed estimates in each of the trailing four quarters, the average surprise being 350.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat
Shares of Inari Medical, Inc. (NARI - Free Report) fell 16.9% on May 5, following the company's first-quarter 2022 results.
The company reported first-quarter 2022 net loss per share of 6 cents, narrower than the Zacks Consensus Estimate of 8 cents. The company had reported earnings of 13 cents per share in the year-ago quarter.
Revenue Details
The company reported revenues of $86.8 million, which surged 51.1% from the prior-year quarter. The top line outpaced the Zacks Consensus Estimate by 4.3%. New product introductions and continued U.S. commercial expansion contributed to the improvement.
Q1 Highlights
The company treated 8,800 patients, up 14% on a sequential basis.
Inari Medical, Inc. Price, Consensus and EPS Surprise
Inari Medical, Inc. price-consensus-eps-surprise-chart | Inari Medical, Inc. Quote
Inari Medical unveiled Intri24 — an introducer sheath created to optimize the FlowTriever procedure. Intri24 has become the latest device to be added to the company’s FlowTriever system of purpose-built tools, all for a single price.
Margins
Gross profit in the reported quarter was $76.8 million, up 45.5% year over year. As a percentage of revenues, gross margin in the quarter was 88.5%, down 340 basis points (bps).
Research and development expenses were $16.1 million, up 97.7% from the year-ago quarter. Meanwhile, selling, general and administrative expenses amounted to $63.7 million, up 72.7% on a year-over-year basis.
Operating loss totaled $3.1 million against the year-ago quarter’s operating income of $7.7 million.
Financial Position
The company exited the first quarter with cash, cash equivalents and short-term investments of $338.7 million, up from $176.1 million on a sequential basis.
Net cash provided by operating activities at the end of the first quarter was $9.1 million, compared with $8.8 million in the prior-year quarter.
2022 Revenue Outlook Revised
For 2022, the company projects revenues in the range of $360 million to $370 million (up from the previously guided range of $350-$360 million). The Zacks Consensus Estimate for the same is pegged at $358.2 million.
Our Take
Inari Medical exited the first quarter on a strong note, wherein both earnings and revenues beat the consensus mark. Apart from treating a large number of patients in the quarter under review, the company made substantial progress on all of its growth drivers.
However, the incurrence of operating loss remains a concern. Contraction in gross margin is a woe.
Zacks Rank
Currently, Inari Medical carries a Zacks Rank #3 (Hold).
Key Picks
Some better-ranked stocks in the broader medical space that have announced quarterly results are Omnicell, Inc. (OMCL - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Alkermes plc (ALKS - Free Report) .
Omnicell, carrying a Zacks Rank #2 (Buy), reported first-quarter 2022 adjusted EPS of 83 cents, which beat the Zacks Consensus Estimate by 16.9%. Revenues of $318.8 million outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Omnicell has an estimated long-term growth rate of 16%. OMCL's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 13.4%.
UnitedHealth, carrying a Zacks Rank #2, reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 1.9%.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.7%.
Alkermes reported first-quarter 2022 adjusted EPS of 12 cents, which beat the Zacks Consensus Estimate of a penny. First-quarter revenues of $278.6 million outpaced the Zacks Consensus Estimate by 6.2%. It currently carries a Zacks Rank #2.
Alkermes has an estimated long-term growth rate of 25.1%. ALKS' earnings surpassed estimates in each of the trailing four quarters, the average surprise being 350.5%.